Grey Matters Health Inc., formerly Algernon Health Inc. and Algernon Pharmaceuticals Inc., reports healthcare developments tied to its shift toward Alzheimer’s disease diagnostics and dedicated brain PET imaging. News for AGNPF has centered on NovaScan Neuroimaging Clinics, U.S. brain PET scanning center plans, CareMiBrain™ scanner technology, beta-amyloid detection, and clinical uses across dementia and other neurologic conditions.
Company updates also cover capital-structure actions, including name changes and share consolidation, equipment financing, service partnerships, clinic leases, and shareholder or governance matters. The company has also described Algernon NeuroScience’s regulated botanical wellness program involving a proprietary form of DMT and its equity interest in Seyltx, which is advancing Ifenprodil for chronic cough.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) announced a discussion regarding its New DMT Stroke Clinical Research Program, featuring CEO Christopher J. Moreau and CSO Dr. Mark Williams, hosted on the BioPub webcast. Scheduled for February 3, 2021, at 12 PM EST, the event welcomes shareholders, investors, and the public to engage in the dialogue about Algernon's innovative approaches in drug repurposing aimed at addressing significant medical needs.
Algernon Pharmaceuticals has launched a clinical research program aimed at treating stroke with AP-188 (DMT), a psychedelic compound. Positioned to be the first globally to trial DMT for stroke in humans, Algernon plans to initiate clinical trials in 2021. The company has filed provisional patents for novel DMT formulations and methods of treatment. This initiative follows promising preclinical studies indicating DMT's potential to enhance neurogenesis and facilitate motor recovery in stroke patients. Algernon aims for a Breakthrough Therapy designation from the U.S. FDA to accelerate the drug's approval process.
Algernon Pharmaceuticals (CSE: AGN) has announced reaching 25% enrollment in its Phase 2 clinical study for NP-120 (Ifenprodil), targeting idiopathic pulmonary fibrosis (IPF) and chronic cough. The study involves 20 patients across 5 sites in Australia and New Zealand. Ifenprodil has shown potential in reducing pulmonary fibrosis and cough frequency in preclinical studies. The company aims to explore Ifenprodil's efficacy in preserving lung function in IPF patients, while continuing its broader development strategy of repurposing existing drugs for new applications.
Algernon Pharmaceuticals has appointed Dr. Mark Swaim to its Medical and Scientific Advisory Board. Dr. Swaim, an accomplished physician and researcher with extensive background in internal medicine and gastroenterology, graduated from Duke University and has previously worked with notable institutions. The company announced the closure of its COVID trial in South Korea due to a lack of patients but continues to push forward with its multinational Phase 2b/3 trial for Ifenprodil, with completion expected in November 2020 and data readout planned by the end of Q4 2020.
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has successfully enrolled 75% of its target for a Phase 2b/3 trial of NP-120 (Ifenprodil) aimed at treating COVID-19, with 113 patients expected for the study. Conducted across the U.S., Australia, Philippines, and Romania, the trial has received approval from the Data and Safety Monitoring Board to proceed. Completion is projected for November 2020, with results anticipated by the end of Q4. The trial aims to assess Ifenprodil's impact alongside standard care on various health metrics of hospitalized patients.